PT  - JOURNAL ARTICLE
AU  - Dixon, Barry
AU  - Smith, Roger J
AU  - Artigas, Antonio
AU  - Laffey, John
AU  - McNicholas, Bairbre
AU  - Schmidt, Eric
AU  - Nunes, Quentin
AU  - Skidmore, Mark
AU  - Lima, Marcelo Andrade de
AU  - Moran, John L
AU  - VanHaren, Frank
AU  - Doig, Gordon
AU  - Ghosh, Angajendra
AU  - Said, Simone
AU  - Gupta, Sachin
AU  - Santamaria, John D
TI  - Protocol of the Can Nebulised Heparin Reduce Time to Extubation in SARS-CoV-2 (CHARTER) Study
AID  - 10.1101/2020.04.28.20082552
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.28.20082552
4099  - http://medrxiv.org/content/early/2020/05/12/2020.04.28.20082552.short
4100  - http://medrxiv.org/content/early/2020/05/12/2020.04.28.20082552.full
AB  - Introduction COVID-19 is associated with the development of ARDS displaying the typical features of diffuse alveolar damage with extensive pulmonary coagulation activation resulting in fibrin deposition in the microvasculature and formation of hyaline membranes in the air sacs. The anti-coagulant actions of nebulised heparin limit fibrin deposition and progression of lung injury. Serendipitously, unfractionated heparin also inactivates the SARS-CoV-2 virus and prevents its entry into mammalian cells. Nebulisation of heparin may therefore limit both fibrin-mediated lung injury and inhibit pulmonary infection by SARS-CoV-2. For these reasons we have initiated a multi-centre international trial of nebulised heparin in patients with COVID-19.Methods and intervention Mechanically ventilated patients with confirmed or strongly suspected SARS-CoV-2 infection, hypoxaemia and an acute pulmonary opacity in at least one lung quadrant on chest X-ray, will be randomised to nebulised heparin 25,000 Units every 6 hours or standard care for up to 10 days while mechanically ventilated. The primary outcome is the time to separation from invasive ventilation to day 28, where non-survivors to day 28 are treated as though not separated from invasive ventilation.Ethics and dissemination The study protocol has been submitted to the human research and ethics committee of St Vincent’s Hospital, Melbourne, Australia. Submission is pending in other jurisdictions. Results of this study will be published in scientific journals and presented at scientific meetings.Trial Registration ACTRN: 12620000517976Competing Interest StatementThe authors have declared no competing interest.Clinical TrialACTRN: 12620000517976Funding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be obtained by contacting the chief investigator